Status:
COMPLETED
Stanford Regulating Circuits of the Brain Study- Ketamine
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Brief Summary
This study is a biomarker study designed to characterize how ketamine impacts the reward circuits of the human brain.
Detailed Description
The investigators will assess the effect of acute ketamine modulation on the functioning of reward-related human brain circuits. Reward-related brain circuits will be assessed using functional magneti...
Eligibility Criteria
Inclusion
- Ages 18-55 years
- At least 2 prior uses of ketamine when aged 18+
- BMI within healthy range (18-30)
- Ability to speak, read, or understand English
Exclusion
- Current active suicide ideation or history of suicide attempts
- Current mood, anxiety, eating, psychotic, or substance use disorder
- Lifetime psychotic or bipolar disorder
- Schizophrenia in a first degree relative
- Current use of psychotropic medication
- Prior adverse ketamine response
- Allergy or hypersensitivity to ketamine
- Use of ketamine in past 7 days
- Cannabis use in the past 7 days, illicit recreational drug use in the 48 hours prior to sessions, and/or alcohol use in the 24 hours prior to sessions
- Concurrent use of any medications that might increase the risk of participation (e.g., drug interactions)
- History of epilepsy, convulsions, seizures, LOC \>10 min
- Renal/hepatic impairment
- Hypertension (Stage 1 defined as systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg on 2 of 3 measurements at least 15 min apart at initial screening; systolic blood pressure \>155 mmHg or diastolic blood pressure \>99 mmHg on 2 of 3 measurements at least 15 min apart during infusion visits)
- Heart rate \<50 bpm or \>150 bpm at initial screening
- Chronic congestive heart failure, tachyarrhythmias, myocardial ischemia assessed via EKG at initial screening
- EKG QTcF intervals \>430 ms for men and \>470 ms for women
- Direct physical access to or routine handling of addicting drugs in the regular course of work duties
- MRI contraindication
- Pregnant or nursing females
Key Trial Info
Start Date :
August 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03475277
Start Date
August 19 2019
End Date
July 1 2024
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Psychiatry
Palo Alto, California, United States, 94304